# Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC

> **NCT06775652** · PHASE3 · COMPLETED · sponsor: **Yongtao Han** · enrollment: 254 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Neoadjuvant Chemoradiotherapy
- **PROCEDURE:** Adjuvant therapy
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT06775652
- **Lead sponsor:** Yongtao Han
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06775652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06775652, "Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06775652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*